Switching between reference adalimumab and biosimilars in chronic immune‐mediated inflammatory diseases: A systematic literature review-Reference-Cited by-同舟云学术

Switching between reference adalimumab and biosimilars in chronic immune‐mediated inflammatory diseases: A systematic literature review

Published:2021-11-02 Issue: Volume: Page:
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

García‐Beloso Nerea¹^ORCID,Altabás‐González Irene²³,Samartín‐Ucha Marisol¹³,Gayoso‐Rey Mónica¹,De Castro‐Parga María Luísa⁴,Salgado‐Barreira Ángel⁵,Cibeira‐Badia Amelia⁶,Piñeiro‐Corrales María Guadalupe¹,González‐Vilas Daniel⁷,Pego‐Reigosa Jose María²³,Martínez‐López de Castro Noemí¹³

Affiliation:

1. Department of Pharmacy University Hospital Complex of Vigo Vigo Spain

2. Department of Rheumatology University Hospital Complex of Vigo Vigo Spain

3. IRIDIS (Investigation in Rheumatology and Immune‐Mediated Diseases) Group Galicia Sur Health Research Institute, SERGAS‐UVIGO Vigo Spain

4. Department of Digestive University Hospital Complex of Vigo Vigo Spain

5. Methodology and Statistics Unit Galicia Sur Health Research Institute (IIS Galicia Sur, SERGAS‐UVIGO Vigo Spain

6. Department of Scientific Library University Hospital Complex of Vigo Vigo Spain

7. Department of Dermatology University Hospital Complex of Vigo Vigo Spain

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15101

Reference54 articles.

1. European Medicines Agency (EMA).Guidelines on similar biological medicinal products. Accessed December 7 2019.http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf

2. US Food and Drug Administration.Guidance for Industry: Scientific considerations in demonstrating biosimilarity to a reference product. Rockville MD: US Food and Drug Administration; 2015. Accessed December 28 2020.https://www.fda.gov/media/82647/download

3. Biosimilar switching—current state of knowledge;Wiland P;Reumatologia,2018

4. Biosimilars in the EU: information guide for health professionals.2019. Accessed October 24 2020.https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf

5. Humira® (adalimumab).Information from the EMA. Accessed October 24 2020.https://www.ema.europa.eu/en/medicines/human/EPAR/humira

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Análisis de la situación de la atención farmacéutica a pacientes con enfermedades inflamatorias inmunomediadas antes y después de la pandemia COVID-19;Farmacia Hospitalaria;2024-06

2. A randomised, crossover trial exploring the patient perspective and effectiveness of biosimilar adalimumab transition: IBD reference and biosimilar adalimumab cross over study (iBaSS);International Journal of Clinical Pharmacy;2024-05-11

3. Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development;Antibodies;2024-02-26

4. Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease;Journal of Clinical Medicine;2023-10-29

5. Biosimilars in the treatment of rheumatoid arthritis: a pharmacokinetic overview;Expert Opinion on Drug Metabolism & Toxicology;2023-10-25